6CM
LENZ

683 Capital Management’s LENZ Therapeutics LENZ Stock Holding History

683 Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-7,472
Closed -$174K – 332
2022
Q4 		$174K Buy
+7,472
New +$173K 0.01% 199

Other funds holding LENZ

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
BOTOTLSJU
Board of Trustees of The Leland Stanford Junior University Redwood City, California $849M AUM 55.45% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $15.4B AUM 30.69% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

683 Capital Management's LENZ Position: Q1 2023 in Review

683 Capital Management sold out of LENZ Therapeutics (LENZ) in Q1 2023, closing a stake of 7,472 shares — an estimated $174K sold.

683 Capital Management first reported a position in LENZ in Q4 2022 and held it in 1 quarter. The position peaked at $174K in Q4 2022. 62 funds tracked by Wall St. Rank hold LENZ as of Q1 2023.

  • 683 Capital Management reported no remaining LENZ Therapeutics position as of Q1 2023 after selling out during the quarter.
  • 683 Capital Management sold 7,472 LENZ Therapeutics shares in Q1 2023, an estimated $174K.
  • 683 Capital Management first reported a position in LENZ Therapeutics in Q4 2022 and held it in 1 quarter.
  • 683 Capital Management's LENZ Therapeutics position peaked at $174K in Q4 2022.
  • 62 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q1 2023.

Based on 683 Capital Management's 13F filing for Q1 2023, filed 15 May 2023.